2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Zenocutuzumab

Zenocutuzumab  (Synonyms: MCLA-128; PB4188; R040517)

製品番号: HY-P99507 純度: 99.9%
COA Technical Support

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1969309-56-5

容量 価格（税別） 在庫状況 数量
1 mg $480 在庫あり
5 mg $1440 在庫あり
10 mg $2300 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Zenocutuzumab Featured Recommendations:

Zenocutuzumab 関連抗体

Top Publications Citing Use of Products

EGFR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

ERBB2/HER2/CD340
体外実験

Zenocutuzumab (0.001-1000 nM; 96 hours) inhibits cell growth in lung and breast cancer cell lines[1].
Zenocutuzumab (0.1-1000 nM; 24 hours) inhibits HER3 and AKT phosphorylation, induces markers of apoptosis and cell cycle arrest in lung and breast cancer cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zenocutuzumab 関連抗体

Cell Viability Assay[1]

Cell Line: Human bronchiolar epithelial cell lines (HBEC)
Concentration: 0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time: 96 h
Result: Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.

Western Blot Analysis[1]

Cell Line: HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells
Concentration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time: 24 hours
Result: Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.
体内実験

Zenocutuzumab (2.5-25 mg/kg; i.p.; once weekly; for 28 days) causes a statistically significant reduction of growth, including tumor regression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1].
Dosage: 2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration: i.p.; once weekly; for 28 days
Result: Blocked growth of lung and ovarian cancer PDX models.
臨床実験
Gene ID

2064  [NCBI] & 2065  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
分子量

145.76 kDa

CAS 番号
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Zenocutuzumab]
輸送条件

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Flow cytometric analysis of 1X106 MCF-7 cells with Zenocutuzumab (HY-P99507, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized HER2/CD340 Protein, Human (HEK293, HY-P73094) can bind Zenocutuzumab. The EC50 for this effect is 2.42 ng/mL.
  • Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Zenocutuzumab. The EC50 for this effect is 31.77 ng/mL.
純度とドキュメンテーション

純度: 99.9%

COA (232 KB) SDS-PAGE (63 KB) SEC-HPLC (157 KB)

Inhibitory Antibodies User Guide (603 KB)
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zenocutuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zenocutuzumab1969309-56-5MCLA-128 PB4188 R040517MCLA128MCLA 128PB4188PB 4188PB-4188R040517R 040517R-040517EGFREpidermal growth factor receptorErbB-1HER1HER2HER3humanized IgG1 antibodySTAT3AKTp70S6Kand S6 phosphorylationInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Zenocutuzumab
製品番号:
HY-P99507
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.